High Expression of MORC2 is Associated with Poor Clinical Outcomes and Immune Infiltrates in Colon Adenocarcinoma

References

• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. doi:10.1016/j.tranon.2021.101174
   PubMed Web of Science ®Google Scholar
• Villéger R, Lopès A, Veziant J, et al. Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol. 2018;24(22):2327–2347. doi:10.3748/wjg.v24.i22
   PubMed Web of Science ®Google Scholar
• Buccafusca G, Proserpio I, Tralongo AC, Rametta Giuliano S, Tralongo P. Early colorectal cancer: diagnosis, treatment and survivorship care. Crit Rev Oncol Hematol. 2019;136:20–30. doi:10.1016/j.critrevonc.2019.01.023
   PubMed Web of Science ®Google Scholar
• Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M. Colorectal Carcinoma: a General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017;18(1):567.
   PubMed Web of Science ®Google Scholar
• Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–732. doi:10.1038/s41575-019-0189-8
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for Colorectal Cancer: a Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst. 2019;111(11):1131–1141. doi:10.1093/jnci/djz093
   PubMedGoogle Scholar
• Li DQ, Nair SS, Kumar R. The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics. 2013;8(7):685–693. doi:10.4161/epi.24976
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28(11):573–576. doi:10.1016/j.tibs.2003.09.003
   PubMed Web of Science ®Google Scholar
• Li DQ, Nair SS, Ohshiro K, et al. MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Rep. 2012;2(6):1657–1669. doi:10.1016/j.celrep.2012.11.018
   PubMed Web of Science ®Google Scholar
• Ding Q-S, Zhang L, Wang B-C, et al. Aberrant high expression level of MORC2 is a common character in multiple cancers. Hum Pathol. 2018;76:58–67. doi:10.1016/j.humpath.2018.03.011
   PubMed Web of Science ®Google Scholar
• Wang G, Song Y, Liu T, et al. PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget. 2015;6(12):9877–9886. doi:10.18632/oncotarget.3185
   PubMedGoogle Scholar
• Zhang Q, Song Y, Chen W, et al. By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget. 2015;6(18):16461–16470. doi:10.18632/oncotarget.3889
   PubMedGoogle Scholar
• Tuupanen S, Hanninen UA, Kondelin J, et al. Identification of 33 candidate oncogenes by screening for base-specific mutations. Br J Cancer. 2014;111(8):1657–1662. doi:10.1038/bjc.2014.429
   PubMed Web of Science ®Google Scholar
• Chen LH, Kuo WH, Tsai MH, et al. Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. PLoS One. 2011;6(11):e28222. doi:10.1371/journal.pone.0028222
   PubMed Web of Science ®Google Scholar
• Lukaszewicz-Zajac M, Mroczko B. Circulating Biomarkers of Colorectal Cancer (CRC)-Their Utility in Diagnosis and Prognosis. J Clin Med. 2021;10(11):567.
   PubMed Web of Science ®Google Scholar
• Han YD, Oh TJ, Chung TH, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019;11(1):51. doi:10.1186/s13148-019-0642-0
   PubMedGoogle Scholar
• Zhang A, Sun H, Yan G, et al. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett. 2014;345(1):17–20. doi:10.1016/j.canlet.2013.11.011
   PubMed Web of Science ®Google Scholar
• Pellino G, Gallo G, Pallante P, et al. Noninvasive Biomarkers of Colorectal Cancer: role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018;2018:2397863. doi:10.1155/2018/2397863
   PubMed Web of Science ®Google Scholar
• Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med. 2019;69:107–122. doi:10.1016/j.mam.2019.06.002
   PubMed Web of Science ®Google Scholar
• Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: current Research and Future Prospects. Int J Mol Sci. 2020;21(15). doi:10.3390/ijms21155311
   PubMed Web of Science ®Google Scholar
• Jin K, Ren C, Liu Y, Lan H, Wang Z. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol. 2020;89(Pt A):107041. doi:10.1016/j.intimp.2020.107041
   PubMedGoogle Scholar
• Shao Y, Li Y, Zhang J, et al. Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic Acids Res. 2010;38(9):2813–2824. doi:10.1093/nar/gkq006
   PubMed Web of Science ®Google Scholar
• Wang GL, Wang CY, Cai XZ, et al. Identification and expression analysis of a novel CW-type zinc finger protein MORC2 in cancer cells. Anat Rec. 2010;293(6):1002–1009. doi:10.1002/ar.21119
   Google Scholar
• Pan Z, Ding Q, Guo Q, et al. MORC2, a novel oncogene, is upregulated in liver cancer and contributes to proliferation, metastasis and chemoresistance. Int J Oncol. 2018;53(1):59–72. doi:10.3892/ijo.2018.4333
   PubMed Web of Science ®Google Scholar
• Koch A, Kang HG, Steinbrenner J, et al. MORC Proteins: novel Players in Plant and Animal Health. Front Plant Sci. 2017;8:1720. doi:10.3389/fpls.2017.01720
   PubMed Web of Science ®Google Scholar
• Sevilla T, Lupo V, Martinez-Rubio D, et al. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain. 2016;139(Pt 1):62–72. doi:10.1093/brain/awv311
   PubMedGoogle Scholar
• Zhang FL, Cao JL, Xie HY, et al. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2018;78(20):5780–5792. doi:10.1158/0008-5472.CAN-17-1394
   PubMed Web of Science ®Google Scholar
• Liao XH, Zhang Y, Dong WJ, Shao ZM, Li DQ. Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1. Oncotarget. 2017;8(58):97941–97954. doi:10.18632/oncotarget.18556
   PubMedGoogle Scholar
• Sanchez-Solana B, Li DQ, Kumar R. Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochim Biophys Acta. 2014;1843(2):316–326. doi:10.1016/j.bbamcr.2013.11.012
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Q, Ruan B, et al. MORC2 regulates C/EBPalpha-mediated cell differentiation via sumoylation. Cell Death Differ. 2019;26(10):1905–1917. doi:10.1038/s41418-018-0259-4
   PubMed Web of Science ®Google Scholar
• Guddeti RK, Chutani N, Pakala SB. MORC2 Interactome: its Involvement in Metabolism and Cancer. Biophys Rev. 2021;13(4):507–514. doi:10.1007/s12551-021-00812-x
   PubMedGoogle Scholar
• Tong Y, Li Y, Gu H, et al. HSF1, in association with MORC2, downregulates ArgBP2 via the PRC2 family in gastric cancer cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt A):1104–1114. doi:10.1016/j.bbadis.2018.01.011
   PubMed Web of Science ®Google Scholar
• Liao G, Liu X, Wu D, et al. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p. Aging. 2019;11(11):3639–3649. doi:10.18632/aging.102003
   PubMedGoogle Scholar
• Liu M, Sun X, Shi S. MORC2 Enhances Tumor Growth by Promoting Angiogenesis and Tumor-Associated Macrophage Recruitment via Wnt/beta-Catenin in Lung Cancer. Cell Physiol Biochem. 2018;51(4):1679–1694. doi:10.1159/000495673
   PubMedGoogle Scholar
• Wang T, Qin ZY, Wen LZ, et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells. Cell Death Differ. 2018;25(12):2086–2100. doi:10.1038/s41418-018-0095-6
   PubMed Web of Science ®Google Scholar
• Liu J, Shao Y, He Y, et al. MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1. Cancer Sci. 2019;110(1):135–146. doi:10.1111/cas.13863
   PubMed Web of Science ®Google Scholar
• Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–6808. doi:10.3748/wjg.v20.i22.6786
   PubMed Web of Science ®Google Scholar
• Ciccolallo L, Capocaccia R, Coleman MP, et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut. 2005;54(2):268–273. doi:10.1136/gut.2004.044214
   PubMed Web of Science ®Google Scholar
• Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–796. doi:10.1016/s1470-2045(07)70246-2
   PubMed Web of Science ®Google Scholar
• Giuliani C. The Flavonoid Quercetin Induces AP-1 Activation in FRTL-5 Thyroid Cells. Antioxidants. 2019;8(5):79.
   Web of Science ®Google Scholar
• Ando M, Okamoto Y, Yoshimura A, et al. Clinical and mutational spectrum of Charcot-Marie-Tooth disease type 2Z caused by MORC2 variants in Japan. Eur J Neurol. 2017;24(10):1274–1282. doi:10.1111/ene.13360
   PubMed Web of Science ®Google Scholar
• Guillen Sacoto MJ, Tchasovnikarova IA, Torti E, et al. De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism. Am J Hum Genet. 2020;107(2):352–363. doi:10.1016/j.ajhg.2020.06.013
   PubMed Web of Science ®Google Scholar
• Liu YY, Liu HY, Yu TJ, et al. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-beta signaling to breast cancer progression. Cell Death Differ. 2022. doi:10.1038/s41418-021-00901-0
   Web of Science ®Google Scholar
• Naccarati A, Polakova V, Pardini B, et al. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis. 2012;27(2):211–218. doi:10.1093/mutage/ger067
   PubMed Web of Science ®Google Scholar
• Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13(28):3784–3791. doi:10.3748/wjg.v13.i28.3784
   PubMed Web of Science ®Google Scholar
• Smith FM, Stephens RB, Kennedy MJ, Reynolds JV. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(9):1813. doi:10.1038/sj.bjc.6602589
   PubMed Web of Science ®Google Scholar
• Lopez I, PO L, Tucci P, et al. Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene. 2012;499(1):81–87. doi:10.1016/j.gene.2012.02.011
   PubMed Web of Science ®Google Scholar
• Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003;21(3):271–276. doi:10.1002/humu.10175
   PubMed Web of Science ®Google Scholar
• Iacopetta B, Russo A, Bazan V, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol. 2006;17(5):842–847. doi:10.1093/annonc/mdl035
   PubMed Web of Science ®Google Scholar
• Sun J, Zhang Z, Bao S, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer. 2020;8(1):34.
   Web of Science ®Google Scholar
• Zhou M, Zhang Z, Bao S, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021;22(3). doi:10.1093/bib/bbaa047
   Web of Science ®Google Scholar
• Kim J, Kwon J, Kim M, et al. Low-dielectric-constant polyimide aerogel composite films with low water uptake. Polymer Journal. 2016;48(7):829–834. doi:10.1038/pj.2016.37
   Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/s0140-6736(18)30789-x
   PubMed Web of Science ®Google Scholar